血塞通注射液治疗血脂异常的系统评价

Systematic Review of Xuesaitong Injection in the Treatment of Dyslipidemia

目的:基于Meta分析方法,系统评价血栓通注射液治疗血脂异常的临床疗效。方法:检索中国知网、万方数据库、维普数据库、the Cochrane Library和PubMed等数据库,收集2012年1月至2022年2月发表的血塞通注射液治疗血脂异常的临床对照研究(两组患者均给予基础治疗和调节血脂药,研究组患者在对照组基础上加用血塞通注射液)。由2名研究人员根据纳入与排除标准进行质量评价并提取相关数据,采用Stata 15.1软件进行Meta分析。结果:共纳入11篇文献(1010例受试者)。分析结果显示,与对照组相比,研究组患者加用血塞通注射液后的总胆固醇(MD=-0.59,95%CI=-0.83~-0.34,P<0.05)、三酰甘油(MD=-0.52,95%CI=-0.80~-0.24,P<0.05)和低密度脂蛋白胆固醇(MD=-0.30,95%CI=-0.48~-0.11,P<0.05)等血脂指标水平显著降低,高密度脂蛋白胆固醇水平(MD=0.24,95%CI=0.14~0.34,P<0.05)显著升高,差异有统计学意义。纳入的文献未提及血塞通注射液发生不良反应。结论:血塞通注射液用于血脂异常患者,能够有效调节其血脂水平,且无明显不良反应。

OBJECTIVE:To systematically review the clinical efficacy of Xuesaitong injection in the treatment of dyslipidemia based on Meta-analysis.METHODS:Controlled clinical trials on Xuesaitong injection in the treatment of dyslipidemia(both groups were given conventional treatment and lipid-regulating drugs,the research group was treated with Xuesaitong injection based on the control group)published from Jan.2012 and Feb.2022 were retrieved from CNKI,Wanfang Data,VIP,the Cochrane Library and PubMed.Quality assessment and data extraction were conducted by two researchers according to the inclusion and exclusion criteria,and Meta-analysis was performed by using Stata 15.1 software.RESULTS:A total of 11 studies(including 1010 subjects)were enrolled.Results of Meta-analysis showed that compared with the control group,patients in the research group given Xuesaitong injection had significantly lower total cholesterol(MD=-0.59,95%CI=-0.83--0.34,P<0.05),triacylglycerol(MD=-0.52,95%CI=-0.80--0.24,P<0.05),low density lipoprotein cholesterin(MD=-0.30,95%CI=-0.48--0.11,P<0.05)levels and significantly higher high density lipoprotein cholesterin(MD=0.24,95%CI=0.14-0.34,P<0.05),with statistically significant differences.No adverse drug reactions related to Xuesaitong injection were mentioned in the involved studies.CONCLUSIONS:The application of Xuesaitong injection on patients with dyslipidemia can effectively regulate blood lipid levels,without any significant adverse drug reactions.